Australians living with multiple sclerosis will continue receiving cheaper access to life-changing treatments after the government decided to keep key drugs on the Pharmaceutical Benefits Scheme (PBS). Health Minister Mark Butler confirmed that Ocrevus, Kesimpta, and Lemtrada will remain subsidized, ending months of uncertainty for patients and manufacturers.
Why Are Some PBS Drugs Under Threat?
The PBS system has faced increasing pressure as pharmaceutical companies threaten to withdraw drugs due to pricing disputes. Several medications have already been pulled or flagged for removal, raising concerns about access to essential treatments. The independent Pharmaceutical Benefits Advisory Committee (PBAC) has called for a rapid review of MS drug use, with a final decision expected by year-end.
Get the #1 Wireless Door Camera
REOLINK Bestseller: 2K Weatherproof Video Doorbell, No Monthly Fees.
How Does the PBS Work?
In Australia, about 90% of medicines are subsidized through the PBS to keep prices low. The PBAC evaluates each drug's health benefits and cost-effectiveness before recommending subsidies. The government then negotiates wholesale prices with manufacturers, while patients pay a flat copayment of $7.70 for pensioners or $25.00 for others. The government covers the difference between wholesale and retail prices.
| Drug | Condition Treated | PBS Status |
|---|---|---|
| Ocrevus | Multiple sclerosis | Remains on PBS |
| Kesimpta | Multiple sclerosis | Remains on PBS |
| Lemtrada | Multiple sclerosis | Remains on PBS |
| Various other drugs | Multiple conditions | Under review or withdrawn |
How Is Trump Involved?
US policy under former President Donald Trump has influenced global pharmaceutical pricing dynamics. Trump's administration pushed for lower drug prices in the US, which led some companies to seek higher profits in other markets like Australia. This has created tension in the PBS system, as manufacturers resist price caps that reduce their revenue. The current review of MS drugs is partly a response to these pressures.
Key Takeaways
- Three major MS drugs remain on the PBS, ensuring affordable access for patients.
- A rapid review of MS drug use is underway, with results due by end of year.
- US policy changes under Trump have strained global drug pricing negotiations.
- Pharmaceutical companies have withdrawn or threatened to withdraw drugs from the PBS due to pricing disputes.
- The PBS system balances affordability for patients with fair compensation for manufacturers.
Frequently Asked Questions
Will I still get my MS medication through the PBS?
Yes, for now. The government has confirmed that Ocrevus, Kesimpta, and Lemtrada will remain on the PBS. However, a rapid review is underway, and a final decision will be made by the end of the year.
Why are some drugs being removed from the PBS?
Pharmaceutical companies have withdrawn drugs due to disagreements over wholesale prices. The PBS system caps costs to keep medicines affordable, but some manufacturers argue the prices are too low to sustain supply.
How does US policy affect Australian drug prices?
US policy, particularly under Trump, has pressured drug companies to lower prices in America. To compensate, some firms seek higher profits abroad, leading to conflicts with Australia's PBS pricing model.
Stay informed about PBS updates and how they impact your healthcare. For more news on Australia's health system, explore other articles on GrandGoldman.com.
Home Decor Shop
Acacia frida deluxe solid wood bed frame |
Bedroom bench |
Bed chest drawers |
Lingerie dresser |
Frame base |
Mirror with jewelry storage |
30 Bathroom Vanity |
Memory foam queen mattress |
Mattresses for back pain |
Nightstand set of 2 |
Grand Goldman Shop |
Civil Lawyer
Deutschland Trikot WM 2026
